ClinicalTrials.gg
CompletedNCT02014558Updated Dec 3, 2024Results posted

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1/2 interventional study of Gilteritinib and Voriconazole in Acute Myeloid Leukemia, sponsored by Astellas Pharma Global Development, Inc.. Completed at 26 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-03.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
265
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute — 13 open to participants now, 15 under way, 6 of them phase 3. gilteritinib · Leukemia, Myeloid, Acute.

Enrollment
11th of 31
265 · median 97
Started
2013
the only one that year
Phase 1/2
8 of 31
2 open now
Registered
1st of 31
by date
Lead sponsor
10 of 31
Astellas Pharma Global Development, Inc.

Among the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, this one is the 11th largest by enrollment, is the only one that started in 2013, is one of 8 in phase 1/2, and was the 1st registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

13 of the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About gilteritinib

gilteritinib: first FDA approval 2018 (XOSPATA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The objective of this study was to assess the safety and tolerability, including the maximum tolerated dose, of gilteritinib in participants with relapsed or treatment-refractory acute myeloid leukemia (AML). This study also determined the pharmacokinetic (PK) parameters of gilteritinib.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • Acute Myeloid Leukemia
  • Gilteritinib
  • ASP2215
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is defined as morphologically documented primary or secondary AML by the World Health Organization (WHO) criteria (2008) and fulfills one of the following:

    • to at least 1 cycle of induction chemotherapy
    • Relapsed after achieving remission with a prior therapy
  • Subject has an (ECOG) performance status ≤ 2.
  • Subject's interval from prior treatment to time of study drug administration is at least 2 weeks for cytotoxic agents (except hydroxyurea given for controlling blast cells), or at least 5 half-lives for prior experimental agents or noncytotoxic agents.
  • Subject must meet the following criteria as indicated on the clinical laboratory tests*:

    • Serum (AST) and alanine aminotransferase (ALT) \<2.5 x institutional upper limit normal ()
    • Total serum \< 1.5x institutional ULN
    • Serum creatinine \< 1.5 x institutional ULN or an estimated (eGFR) of > 50 ml/min as calculated by the Modification of Diet in Renal Disease (MDRD) equation.
  • Subject agrees not to participate in another interventional study while on treatment.

Exclusion criteria

Exclusion Criteria:

  • Subject was diagnosed as acute promyelocytic leukemia (APL).
  • Subject has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
  • Subject has active malignant tumors other than AML or Myelodysplastic syndrome (MDS).
  • Subject has persistent nonhematological toxicities of >= Grade 2 ( v4), with symptoms and objective findings, from prior AML treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation, or surgery).
  • Subject has had hematopoietic stem cell transplant () and meets any of the following:

    • Is within 2 months of transplant from C1D1
    • Has requiring treatment
    • Has >= Grade 2 persistent non-hematological toxicity related to the transplant. Donor lymphocytes infusion (DLI) is not permitted \<= 30 days prior to study registration or during the first cycle of treatment on the study in Cohort 1 and first two cycles of the treatment in Cohort 2
  • Subject has clinically active central nervous system leukemia
  • Subject has disseminated intravascular coagulation abnormality (DIC)
  • Subject has had major surgery within 4 weeks prior to the first study dose.
  • Subject has had radiation therapy within 4 weeks prior to the first study dose
  • Subject has congestive heart failure (NYHA) class 3 or 4, or subject with a history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram performed within 3 months prior to study entry results in a that is ≥ 45%
  • Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of Cytochrome P450-isozyme3A4 () with the exception of antibiotics, antifungals, and antivirals that are used as standard of care post-transplant or to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the subject
  • Subject required treatment with concomitant drugs that target serotonin 5HT1R or 5HT2BR receptors or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.
  • Subject has an active uncontrolled infection
  • Subject is known to have infection
  • Subject has active or C, or other active hepatic disorder
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
265 participants (actual)

Study arms

  • Experimental
    Gilteritinib 20 mg in Escalation Phase

    Participants received a single dose of 20 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 20 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.

    Drug: Gilteritinib · Drug: Voriconazole

  • Experimental
    Gilteritinib 40 mg in Escalation Phase

    Participants received a single dose of 40 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 40 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.

    Drug: Gilteritinib

  • Experimental
    Gilteritinib 80 mg in Escalation Phase

    Participants received a single dose of 80 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 80 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.

    Drug: Gilteritinib

  • Experimental
    Gilteritinib 120 mg in Escalation Phase

    Participants received a single dose of 120 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 120 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.

    Drug: Gilteritinib

  • Experimental
    Gilteritinib 200 mg in Escalation Phase

    Participants received a single dose of 200 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 200 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.

    Drug: Gilteritinib

  • Experimental
    Gilteritinib 300 mg in Escalation Phase

    Participants received a single dose of 300 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 300 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.

    Drug: Gilteritinib

  • Experimental
    Gilteritinib 450 mg in Escalation Phase

    Participants received a single dose of 450 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 450 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.

    Drug: Gilteritinib

  • Experimental
    Gilteritinib 20 mg in Expansion Phase

    Participants received 20 mg gilteritinib orally once daily stating on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. Starting on day 16 of cycle 1, participants also received 200 mg voriconazole orally every 12 hours through day 1 of cycle 2.

    Drug: Gilteritinib

  • Experimental
    Gilteritinib 40 mg in Expansion Phase

    Participants received 40 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.

    Drug: Gilteritinib

  • Experimental
    Gilteritinib 80 mg in Expansion Phase

    Participants received 80 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.

    Drug: Gilteritinib

  • Experimental
    Gilteritinib 120 mg in Expansion Phase

    Participants received 120 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.

    Drug: Gilteritinib

  • Experimental
    Gilteritinib 200 mg in Expansion Phase

    Participants received 200 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. On day -1 and day 15 of cycle 1, certain participants also received 500 mg cephalexin as a single oral dose.

    Drug: Gilteritinib · Drug: Cephalexin

  • Experimental
    Gilteritinib 300 mg in Expansion Phase

    Participants received 300 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. On day -1 and day 15 of cycle 1, participants also received 2 mg midazolam as a single oral dose.

    Drug: Gilteritinib · Drug: Midazolam

Interventions

  • Participants received gilteritinib oral tablets (10 mg, 40 mg or 100 mg, depending on the dose) once daily without food allowed for at least 2 hours before and 1 hour after dosing starting from day -2 and day of cycle 1, for continuous 28-day cycles.

    Also known as: ASP2215

  • Participants received 200 mg voriconazole tablets daily every 12 hours starting from day 16 of cycle 1 through day 1 of cycle 2.

  • Participants received a single oral dose of 2 mg of midazolam syrup on day -1 and day 15 of cycle 1.

  • Participants received a single oral dose of 500 mg cephalexin tablet or capsule on day -1 and day 15 of cycle 1.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities (DLTs)

    To determine the maximum tolerated dose, safety was assessed by DLTs, defined as any grade ≥ 3 non-hematologic or extramedullary toxicity that occurred within 30 days starting with the first dose taken on day -2, and included the first treatment cycle in the dose escalation phase and in the first treatment cycle (28 days) in the dose expansion phase, that was considered to be possibly or probably related to study drug. Exceptions to this were the following: (1) Alopecia, anorexia or fatigue, (2) Grade 3 nausea and/or vomiting if not required tube feeding or total parenteral nutrition, or diarrhea if not required or prolonged hospitalization that was managed to grade ≤ 2 with standard antiemetic or antidiarrheal medications used at prescribed dose within 7 days of onset, (3) Grade 3 fever with neutropenia, with or without infection, (4) Grade 3 infection.

    Time frame: From first dose up to end of cycle 1 (30 days)

  2. Number of Participants With Adverse Events (AEs)

    Safety was assessed by AEs, which included abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.) if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. A treatment-emergent AE (TEAE) was defined as an AE observed after starting administration of the study drug up to 30 days after last dose of study drug (for participants who underwent hematopoietic stem cell transplantation \[HSCT\]: defined as AEs observed after starting study drug until the last dose before on study HSCT plus 30 days, and AEs that began after resumption of gilteritinib and within 30 days after the last dose of gilteritinib). AEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (1-Mild, 2-Moderate, 3-Severe, 4-LifeThreatening, 5-Death).

    Time frame: From first dose of study drug up to 30 days after last dose of study drug (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  3. Area Under the Concentration-time Curve Over the 24-Hour Dosing Interval (AUC24) After Single and Multiple Doses of Gilteritinib

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Day -2 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose

  4. Maximum Concentration (Cmax) After Single and Multiple Doses of Gilteritinib

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Day -2 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose

  5. Area Under the Concentration-time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) After Single and Multiple Doses of Gilteritinib

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Day -2 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose

  6. Time to Observed Cmax (Tmax) After Single and Multiple Doses of Gilteritinib

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Day -2 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose

  7. Terminal Elimination Half-life (t1/2) After Multiple Doses of Gilteritinib

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose

  8. Accumulation Ratio After Multiple Doses of Gilteritinib

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose

Secondary outcomes

  1. Percentage of Participants With Complete Remission (CR) During the First 2 Cycles

    CR was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CR when they had bone marrow regenerating normal hematopoietic cells, achieved a morphologic leukemia-free state, had an absolute neutrophil count (ANC) \> 1 x 10\^9/L, platelet count ≥ 100 x 10\^9/L, normal marrow differential with \< 5% blasts, had been red blood cell (RBC) and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion), had no presence of Auer rods and no evidence of extramedullary leukemia, and blast counts in peripheral blood had been ≤ 2%. Exact 95% confidence interval was estimated using binomial distribution.

    Time frame: During the first 2 cycles (56 days)

  2. Percentage of Participants With CR During Treatment

    CR was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CR when they had bone marrow regenerating normal hematopoietic cells, achieved a morphologic leukemia-free state, had an absolute neutrophil count (ANC) \> 1 x 10\^9/L, platelet count ≥ 100 x 10\^9/L, normal marrow differential with \< 5% blasts, had been red blood cell (RBC) and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion), had no presence of Auer rods and no evidence of extramedullary leukemia, and blast counts in peripheral blood had been ≤ 2%. Exact 95% confidence interval was estimated using binomial distribution.

    Time frame: Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  3. Percentage of Participants With CR With Incomplete Platelet Recovery (CRp)

    CRp was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CRp when they achieved CR except for incomplete platelet recovery (\< 100 x 10\^9/L). Exact 95% confidence interval was estimated using the binomial distribution.

    Time frame: Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  4. Percentage of Participants With CR With Incomplete Hematological Recovery (CRi)

    CRi was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CRi when they fulfilled all the criteria for CR except for incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence were not required. Exact 95% confidence interval was estimated using the binomial distribution.

    Time frame: Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  5. Percentage of Participants With Complete Remission With Partial Hematologic Recovery (CRh)

    CRh was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CRh when they could not be classified as being in CR and had bone marrow blasts \< 5% and partial hematologic recovery ANC \>= 0.5 x 10\^9/L and platelets \>= 50 x 10\^9/L. There should not be evidence of extramedullary leukemia. Exact 95% confidence interval was estimated using the binomial distribution. CRh was calculated only for participants who were FLT3 mutation positive.

    Time frame: Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  6. Percentage of Participants With Composite CR (CRc)

    CRc was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CRc when they had achieved either CR, complete remission with incomplete platelet recovery (CRp, defined as had achieved CR except for incomplete platelet recovery (\< 100 x 10\^9/L) or complete remission with incomplete hematologic recovery (CRi, defined as had fulfilled all the criteria for CR except for incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery; RBC platelet transfusion independence not required). Exact 95% confidence interval was estimated using the binomial distribution.

    Time frame: Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  7. Percentage of Participants With Partial Remission (PR)

    PR was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in PR when they had bone marrow regenerating normal hematopoietic cells with evidence of peripheral recovery with no (or only a few regenerating) circulating blasts and with a decrease of at least 50% in the percentage of blasts in the bone marrow aspirate with the total marrow blasts between 5% and 25%. A value of less or equal than 5% blasts was also considered a PR if Auer rods were present. There should be no evidence of extramedullary leukemia. Exact 95% confidence interval was estimated using the binomial distribution.

    Time frame: Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  8. Percentage of Participants With Best Response

    Best response was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). BR was defined as the best measured response for all visits (in the order of CR, CRp, CRi, and PR) post-treatment. Participants who achieved the best response of CR, CRp, CRi or PR were classified as responders. Participants who did not achieve at least PR were considered as non-responders. Exact 95% confidence interval was estimated using the binomial distribution.

    Time frame: Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  9. Percentage of Participants With Complete Remission and Complete Remission With Partial Hematologic Recovery (CR/CRh)

    Participants with CR/CRh were defined as participants who achieved either CR or CRh. Participants with CR had bone marrow regenerating normal hematopoietic cells, achieved a morphologic leukemia-free state, had an ANC \> 1 x 10\^9/L, platelet count ≥ 100 x 10\^9/L, and normal marrow differential with \< 5% blasts, had been RBC and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion). Also, there had been no presence of Auer rods, no evidence of extramedullary leukemia, and blast counts in peripheral blood had been ≤ 2%. Participants with CRh could not be classified as being in CR and had bone marrow blasts \< 5%, partial hematologic recovery ANC \>= 0.5 x 10\^9/L and platelets \>= 50 x 10\^9/L. There should not be evidence of extramedullary leukemia. Exact 95% confidence interval was estimated using the binomial distribution. CR/CRh was calculated only for participants who were FLT3 mutation positive.

    Time frame: Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  10. Duration of CR (DCR)

    DCR was defined as the time from the date of first CR until the date of documented relapse for participants who achieved CR. Participants who died without report of relapse were considered non-events and censored at their last relapse-free disease assessment date. Other participants who did not relapse on study were considered non-events and censored at the last relapse-free disease assessment date. DCR was calculated using Kaplan-Meier method and therefore data are estimated.

    Time frame: From date of remission until end of study (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  11. Duration of CRp (DCRp)

    DCRp was defined as the time from the date of first CRp until the date of documented relapse for participants who achieved CRp. Participants who died without report of relapse were considered non-events and censored at their last relapse-free disease assessment date. Other participants who did not relapse on study were considered non-events and censored at the last relapse-free disease assessment date. DCRp was calculated using Kaplan-Meier method and therefore data are estimated.

    Time frame: From date of remission until end of study (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  12. Duration of CRi (DCRi)

    DCRi was defined as the time from the date of first CRi until the date of documented relapse for participants who achieved CRi. Participants who died without report of relapse and participants who did not relapse were considered non-events and censored at the last relapse-free disease assessment date. DCRi was calculated using Kaplan-Meier method and therefore data are estimated.

    Time frame: From date of remission until end of study (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  13. Duration of CRh (DCRh)

    DCRh was defined as the time from the date of first CRh until the date of documented relapse for participants who achieved CRh but did not have a best response of CR. Participants who died without report of relapse and participants who did not relapse were considered non-events and censored at the last relapse-free disease assessment date. DCRh was calculated using Kaplan-Meier method and therefore data are estimated. DCRh was calculated only for participants who were FLT3 mutation positive.

    Time frame: From date of remission until end of study (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  14. Duration of CRc (DCRc)

    DCRc was defined as the time from the date of first CRc until the date of documented relapse for participants who achieved CRc. Participants who died without report of relapse and participants who did not relapse were considered non-events and censored at the last relapse-free disease assessment date. DCRc was calculated using Kaplan-Meier method and therefore data are estimated.

    Time frame: From date of remission until end of study (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  15. Duration of CR/CRh (DCRCRh)

    DCRCRh was defined as the time from the date of first DCRCRh until the date of documented relapse for participants who achieved CR or CRh. For participants who achieved both CR and CRh, the first CR date or CRh date, whichever occurred first, was used. Participants who died without report of relapse and participants who did not relapse were considered non-events and censored at the last relapse-free disease assessment date. DCRCRh was calculated using Kaplan-Meier method and therefore data are estimated. DCRCRh was calculated only for participants who were FLT3 mutation positive.

    Time frame: From date of remission until end of study (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  16. Duration of Response

    Duration of response was defined as the time from the date of either first CRc or PR until the date of documented relapse of any type for participants who achieved CRc or PR. Participants who died without report of relapse were considered non-events and censored at their last relapse-free disease assessment date. Other participants who did not relapse on study are considered non-events and censored at the last relapse-free assessment date. Duration of response was calculated using Kaplan-Meier method and therefore data are estimated.

    Time frame: From date of remission until end of study (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  17. Time to CR (TTCR)

    TTCR was defined as the time from the first dose of study drug until the date of first CR.

    Time frame: From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  18. Time to CRp (TTCRp)

    TTCRp was defined as the time from the first dose of study drug until the date of first CRp. TTCRp was evaluated for participants who achieved CRp.

    Time frame: From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  19. Time to CRi (TTCRi)

    TTCRi was defined as the time from the first dose of study drug until the date of first CRi. TTCRi was evaluated for participants who achieved CRi.

    Time frame: From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  20. Time to First CR/CRh (TTFCRCRh)

    TTFCRCRh was defined as the time from the first dose of study drug until the date of first either CR or CRh. TTFCRCRh was evaluated for participants who achieved CR or CRh. For participants who achieve both CR and CRh, the first CR date or CRh date, whichever occurs first was used. TTFCRCRh was calculated only for participants who were FLT3 mutation positive.

    Time frame: From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  21. Time to Best CR/CRh (TTBCRCRh)

    TTBCRCRh was defined as the time from the first dose of study drug until the first date that the best response of CR or CRh was achieved. TTBCRCRh was evaluated for participants who achieved CR or CRh. For participants who achieve both CR and CRh, the first CR date was used. TTBCRCRh was calculated only for participants who were FLT3 mutation positive.

    Time frame: From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  22. Time to CRc (TTCRc)

    TTCRc was defined as the time from the first dose of study drug until the date of first CRc. TTCRc was evaluated for participants who achieved CRc.

    Time frame: From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  23. Time to Response (TTR)

    TTR was defined as the time from the first dose of study drug until the date of either first CRc or PR. TTR was evaluated for participants who achieved CRc or PR.

    Time frame: From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  24. Time to Best Response (TTBR)

    TTBR was defined as the time from the first dose of study drug until the first disease assessment date when participant achieved best response. TTBR was evaluated in participants who achieved best response of CR, CRp, CRi, or PR.

    Time frame: From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)

  25. Overall Survival (OS)

    The time from the date of first dose of study drug until the date of death from any cause. For a participant who was not known to have died by the end of study follow-up, OS was censored at the date of last contact. OS was calculated using Kaplan-Meier method and therefore data are estimated.

    Time frame: From first dose of study drug up to end of study (median time on study was 157.0 days, minimum of 5 days and maximum of 1320 days)

  26. Event Free Survival (EFS)

    EFS was defined as the time from the date of first dose of study drug until the date of documented relapse, treatment failure or death from any cause, whichever occurred first. For a participant with none of these events, EFS was censored at the date of last relapse-free disease assessment. A participant without post-treatment disease assessment was censored at randomization date. Treatment failure included those participants who discontinued the treatment due to "progressive disease" or "lack of efficacy" without a previous response of CR, CRp, CRi or PR. Treatment failure date referred to the start of new anti-leukemia therapy or the last treatment evaluation date when new anti-leukemia therapy date was not available. For participants who were censored, last relapse-free disease assessment date referred to the participant's last disease assessment date. EFS was calculated using Kaplan-Meier method and therefore data are estimated.

    Time frame: From first dose of study drug up to end of study (median time on study was 157.0 days, minimum of 5 days and maximum of 1320 days)

  27. Leukemia Free Survival (LFS)

    LFS was defined as the time from the date of first CRc until the date of documented relapse or death for participants who achieved CRc. For a participant who was not known to have relapsed or died, LFS was censored on the date of last relapse-free disease assessment date. LFS was calculated using Kaplan-Meier method and therefore data are estimated.

    Time frame: From first dose of study drug up to end of study (median time on study was 157.0 days, minimum of 5 days and maximum of 1320 days)

  28. Percentage of Participants Who Achieved Transfusion Conversion

    Participants who achieved transfusion conversion were defined as the number of participants who were transfusion dependent at baseline period but became transfusion independent at post-baseline period divided by the total number of participants who were transfusion dependent at baseline period. Participants were considered baseline transfusion dependent if there were RBC or platelet transfusions within the baseline period. Participants were considered post-baseline transfusion independent if they were on treatment \>=84 days, and if there was one consecutive 56 days without any RBC or platelet transfusion within post-baseline period. If participants were on treatment \>28 days but \<84 days, and there was no RBC or platelet transfusion within post-baseline period, or on treatment \<=28 days, post-baseline transfusion status was not evaluable. Exact 95% confidence interval was estimated using the binomial distribution.

    Time frame: Baseline (28 days prior to first dose until 28 days after the first dose) and postbaseline (from 29 days after first dose date until last dose date); median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days

  29. Percentage of Participants Who Achieved Transfusion Maintenance

    Participants who achieved transfusion maintenance were defined as the number of participants who were transfusion independent at baseline period and still maintained transfusion independent at post-baseline period divided by the total number of participants who were transfusion independent at baseline period.

    Time frame: Baseline (28 days prior to first dose until 28 days after the first dose) and postbaseline (from 29 days after first dose date until last dose date); median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days

  30. AUC24 of Gilteritinib in Co-administration With Voriconazole

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Cycle 1 Day 15 and Cycle 2 Day 1: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (gilteritinib)

  31. Cmax of Gilteritinib in Co-administration With Voriconazole

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Cycle 1 Day 15 and Cycle 2 Day 1: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (gilteritinib)

  32. AUClast of Gilteritinib in Co-administration With Voriconazole

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Cycle 1 Day 15 and Cycle 2 Day 1: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (gilteritinib)

  33. Tmax of Gilteritinib in Co-administration With Voriconazole

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Cycle 1 Day 15 and Cycle 2 Day 1: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (gilteritinib)

  34. AUC24 of Midazolam Administered With and Without Gilteritinib

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)

  35. AUC24 of Metabolite 1-Hydroxymidazolam After Administration of Midazolam With and Without Gilteritinib

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)

  36. Cmax of Midazolam Administered With and Without Gilteritinib

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)

  37. Cmax of 1-Hydroxymidazolam After Administration of Midazolam With and Without Gilteritinib

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)

  38. AUClast of Midazolam Administered With and Without Gilteritinib

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)

  39. AUClast of 1-Hydroxymidazolam After Administration of Midazolam With and Without Gilteritinib

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)

  40. Tmax of Midazolam Administered With and Without Gilteritinib

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)

  41. Tmax of 1-Hydroxymidazolam After Administration of Midazolam With and Without Gilteritinib

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)

  42. Area Under the Concentration-time Curve From the Time of Dosing Extrapolated to Time Infinity (AUCinf) of Cephalexin Administered With and Without Gilteritinib

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 1.5, 2, 3, 4, 6, 24 hours postdose (cephalexin)

  43. Cmax of Cephalexin Administered With and Without Gilteritinib

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 1.5, 2, 3, 4, 6, 24 hours postdose (cephalexin)

  44. AUClast of Cephalexin Administered With and Without Gilteritinib

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 1.5, 2, 3, 4, 6, 24 hours postdose (cephalexin)

  45. Tmax of Cephalexin Administered With and Without Gilteritinib

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 1.5, 2, 3, 4, 6, 24 hours postdose (cephalexin)

  46. T1/2 of Cephalexin Administered With and Without Gilteritinib

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 1.5, 2, 3, 4, 6, 24 hours postdose (cephalexin)

  47. Apparent Total Systemic Clearance After Single or Multiple Extravascular Dosing (CL/F) of Cephalexin Administered With and Without Gilteritinib

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 1.5, 2, 3, 4, 6, 24 hours postdose (cephalexin)

  48. Apparent Volume of Distribution During the Terminal Elimination Phase After Single Extravascular Dosing (Vz/F) of Cephalexin Administered With and Without Gilteritinib

    Plasma samples were used for pharmacokinetic assessments.

    Time frame: Day -1 and cycle 1 day 15: predose, 0.5, 1, 1.5, 2, 3, 4, 6, 24 hours postdose (cephalexin)

  49. Amount of Drug Excreted in Urine (Aelast) of Cephalexin Administered With and Without Gilteritinib

    Urine samples were used for pharmacokinetic assessments.

    Time frame: Day -1 and cycle 1 day 15: 0-3 hours, 3-6 hours, 6-24 hours postdose (cephalexin)

  50. Fraction of Drug Excreted Into Urine in Percentage (%Ae) of Cephalexin Administered With and Without Gilteritinib

    Urine samples were used for pharmacokinetic assessments.

    Time frame: Day -1 and cycle 1 day 15: 0-3 hours, 3-6 hours, 6-24 hours postdose (cephalexin)

  51. Renal Clearance (CLr) of Cephalexin in Administered With and Without Gilteritinib

    Urine samples were used for pharmacokinetic assessments.

    Time frame: Day -1 and cycle 1 day 15: 0-3 hours, 3-6 hours, 6-24 hours postdose (cephalexin)

07

Results

Posted Feb 20, 2019

Participant flow

This dose-escalation/dose-expansion study was conducted in sites in the United States, France, Germany and Italy. The study had 7 dose-escalation cohorts with ≥3 participants enrolled at each dose level. Following escalation to the next dose cohort, additional participants were enrolled to the dose-expansion cohorts per protocol-specified criteria.

Participant flow — Overall Study
MilestoneGilteritinib 20 mg in Escalation PhaseGilteritinib 40 mg in Escalation PhaseGilteritinib 80 mg in Escalation PhaseGilteritinib 120 mg in Escalation PhaseGilteritinib 200 mg in Escalation PhaseGilteritinib 300 mg in Escalation PhaseGilteritinib 450 mg in Escalation PhaseGilteritinib 20 mg in Expansion PhaseGilteritinib 40 mg in Expansion PhaseGilteritinib 80 mg in Expansion PhaseGilteritinib 120 mg in Expansion PhaseGilteritinib 200 mg in Expansion PhaseGilteritinib 300 mg in Expansion Phase
Started53334341115216910217
Treated53333331213216610017
Completed0000000000000
Not completed53334341115216910217
Withdrew: Never received study drug0000101020220
Withdrew: Adverse event00001000225213
Withdrew: Death10000011255192
Withdrew: Lack of efficacy12110013331685
Withdrew: Lost to follow-up0000000000100
Withdrew: Progressive disease101112165622316
Withdrew: Withdrawal by subject00001000026100
Withdrew: Miscellaneous211101011312111

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities (DLTs)

To determine the maximum tolerated dose, safety was assessed by DLTs, defined as any grade ≥ 3 non-hematologic or extramedullary toxicity that occurred within 30 days starting with the first dose taken on day -2, and included the first treatment cycle in the dose escalation phase and in the first treatment cycle (28 days) in the dose expansion phase, that was considered to be possibly or probably related to study drug. Exceptions to this were the following: (1) Alopecia, anorexia or fatigue, (2) Grade 3 nausea and/or vomiting if not required tube feeding or total parenteral nutrition, or diarrhea if not required or prolonged hospitalization that was managed to grade ≤ 2 with standard antiemetic or antidiarrheal medications used at prescribed dose within 7 days of onset, (3) Grade 3 fever with neutropenia, with or without infection, (4) Grade 3 infection.

Time frame:
From first dose up to end of cycle 1 (30 days)
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsGilteritinib 20 mg in Escalation PhaseGilteritinib 40 mg in Escalation PhaseGilteritinib 80 mg in Escalation PhaseGilteritinib 120 mg in Escalation PhaseGilteritinib 200 mg in Escalation PhaseGilteritinib 300 mg in Escalation PhaseGilteritinib 450 mg in Escalation PhaseGilteritinib 20 mg in Expansion PhaseGilteritinib 40 mg in Expansion PhaseGilteritinib 80 mg in Expansion PhaseGilteritinib 120 mg in Expansion PhaseGilteritinib 200 mg in Expansion PhaseGilteritinib 300 mg in Expansion Phase
Any DLT00000021127153
Blood and lymphatic system disorders0000000000001
Cardiac disorders0000000000100
Eye disorders0000000001000
Gastrointestinal disorders0000001000141
General disorders & administration site conditions0000000000010
Hepatobiliary disorders0000000000100
Infections and infestations0000000011000
Investigations0000001000262
Metabolism and nutrition disorders0000000000020
Musculoskeletal and connective tissue disorders0000000000011
Nervous system disorders0000000100030
Renal and urinary disorders0000000000100
Reproductive system and breast disorders0000000000010
Respiratory, thoracic and mediastinal disorders0000000000121
Vascular disorders0000000000021
PrimaryNumber of Participants With Adverse Events (AEs)

Safety was assessed by AEs, which included abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.) if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. A treatment-emergent AE (TEAE) was defined as an AE observed after starting administration of the study drug up to 30 days after last dose of study drug (for participants who underwent hematopoietic stem cell transplantation \[HSCT\]: defined as AEs observed after starting study drug until the last dose before on study HSCT plus 30 days, and AEs that began after resumption of gilteritinib and within 30 days after the last dose of gilteritinib). AEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (1-Mild, 2-Moderate, 3-Severe, 4-LifeThreatening, 5-Death).

Time frame:
From first dose of study drug up to 30 days after last dose of study drug (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsGilteritinib 20 mg in Escalation PhaseGilteritinib 40 mg in Escalation PhaseGilteritinib 80 mg in Escalation PhaseGilteritinib 120 mg in Escalation PhaseGilteritinib 200 mg in Escalation PhaseGilteritinib 300 mg in Escalation PhaseGilteritinib 450 mg in Escalation PhaseGilteritinib 20 mg in Expansion PhaseGilteritinib 40 mg in Expansion PhaseGilteritinib 80 mg in Expansion PhaseGilteritinib 120 mg in Expansion PhaseGilteritinib 200 mg in Expansion PhaseGilteritinib 300 mg in Expansion Phase
AEs53333331213206410017
Drug-Related AEs32133237617527713
Deaths2201111341123497
Serious AEs222122281219529214
Drug-Related Serious AEs0001102211019364
AEs Leading to Discontinuation of Study Drug2010101251112466
Drug-Related AEs Leading to Discont. of Study Drug00000001145103
Grade 3 or Higher TEAEs322122391320599914
AEs During On-Study HSCT Period0000000000370
Serious AEs During On-Study HSCT0000000000030
PrimaryArea Under the Concentration-time Curve Over the 24-Hour Dosing Interval (AUC24) After Single and Multiple Doses of Gilteritinib

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Day -2 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose
Reported as:
Mean · ng*h/mL
Area Under the Concentration-time Curve Over the 24-Hour Dosing Interval (AUC24) After Single and Multiple Doses of Gilteritinib
ng*h/mLGilteritinib 20 mg in Escalation PhaseGilteritinib 40 mg in Escalation PhaseGilteritinib 80 mg in Escalation PhaseGilteritinib 120 mg in Escalation PhaseGilteritinib 200 mg in Escalation PhaseGilteritinib 300 mg in Escalation PhaseGilteritinib 450 mg in Escalation Phase
Day -2302.1 ± 207.0360.0 ± 223.51216 ± 472.62480 ± 19723022 ± 843.64163 ± 31783324 ± 221.1
Cycle 1 Day 151299 ± 10062482 ± 33.286958 ± 32736943 ± 322131428 ± 2141231005 ± 1006834768 ± NA
Statistical analysis
  • Gilteritinib 20 mg in Escalation Phase vs Gilteritinib 40 mg in Escalation Phase vs Gilteritinib 80 mg in Escalation Phase vs Gilteritinib 120 mg in Escalation Phase vs Gilteritinib 200 mg in Escalation Phase vs Gilteritinib 300 mg in Escalation Phase vs Gilteritinib 450 mg in Escalation Phase · Slope: 0.990 · 90% CI 0.788 to 1.19
  • Gilteritinib 20 mg in Escalation Phase vs Gilteritinib 40 mg in Escalation Phase vs Gilteritinib 80 mg in Escalation Phase vs Gilteritinib 120 mg in Escalation Phase vs Gilteritinib 200 mg in Escalation Phase vs Gilteritinib 300 mg in Escalation Phase vs Gilteritinib 450 mg in Escalation Phase · Slope: 1.22 · 90% CI 1.00 to 1.43
PrimaryMaximum Concentration (Cmax) After Single and Multiple Doses of Gilteritinib

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Day -2 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose
Reported as:
Mean · ng/mL
Maximum Concentration (Cmax) After Single and Multiple Doses of Gilteritinib
ng/mLGilteritinib 20 mg in Escalation PhaseGilteritinib 40 mg in Escalation PhaseGilteritinib 80 mg in Escalation PhaseGilteritinib 120 mg in Escalation PhaseGilteritinib 200 mg in Escalation PhaseGilteritinib 300 mg in Escalation PhaseGilteritinib 450 mg in Escalation Phase
Day -228.13 ± 21.4924.98 ± 14.5875.29 ± 25.22136.7 ± 94.37168.2 ± 45.34204.3 ± 136.4207.6 ± 51.81
Cycle 1 day 1564.64 ± 48.77107.6 ± 31.92376.4 ± 150.5374.2 ± 190.11462 ± 815.11525 ± 664.61528 ± NA
Statistical analysis
  • Gilteritinib 20 mg in Escalation Phase vs Gilteritinib 40 mg in Escalation Phase vs Gilteritinib 80 mg in Escalation Phase vs Gilteritinib 120 mg in Escalation Phase vs Gilteritinib 200 mg in Escalation Phase vs Gilteritinib 300 mg in Escalation Phase vs Gilteritinib 450 mg in Escalation Phase · Slope: 0.808 · 90% CI 0.629 to 0.988
  • Gilteritinib 20 mg in Escalation Phase vs Gilteritinib 40 mg in Escalation Phase vs Gilteritinib 80 mg in Escalation Phase vs Gilteritinib 120 mg in Escalation Phase vs Gilteritinib 200 mg in Escalation Phase vs Gilteritinib 300 mg in Escalation Phase vs Gilteritinib 450 mg in Escalation Phase · Slope: 1.21 · 90% CI 1.02 to 1.41
PrimaryArea Under the Concentration-time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) After Single and Multiple Doses of Gilteritinib

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Day -2 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose
Reported as:
Mean · ng*h/mL
Area Under the Concentration-time Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) After Single and Multiple Doses of Gilteritinib
ng*h/mLGilteritinib 20 mg in Escalation PhaseGilteritinib 40 mg in Escalation PhaseGilteritinib 80 mg in Escalation PhaseGilteritinib 120 mg in Escalation PhaseGilteritinib 200 mg in Escalation PhaseGilteritinib 300 mg in Escalation PhaseGilteritinib 450 mg in Escalation Phase
Day -2303.0 ± 207.1360.4 ± 224.11216 ± 472.62480 ± 19723024 ± 846.24181 ± 31892544 ± 1427
Cycle 1 day -151030 ± 984.21990 ± 14227111 ± 35256943 ± 322132248 ± 2257131749 ± 1009035506 ± NA
PrimaryTime to Observed Cmax (Tmax) After Single and Multiple Doses of Gilteritinib

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Day -2 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose
Reported as:
Median · hours
Time to Observed Cmax (Tmax) After Single and Multiple Doses of Gilteritinib
hoursGilteritinib 20 mg in Escalation PhaseGilteritinib 40 mg in Escalation PhaseGilteritinib 80 mg in Escalation PhaseGilteritinib 120 mg in Escalation PhaseGilteritinib 200 mg in Escalation PhaseGilteritinib 300 mg in Escalation PhaseGilteritinib 450 mg in Escalation Phase
Day -22.00 (0.500 to 4.03)5.983 (3.97 to 24.0)4.000 (4.00 to 4.08)2.083 (2.00 to 3.83)5.233 (4.00 to 5.97)6.067 (4.08 to 24.1)5.783 (4.08 to 5.92)
Cycle 1 day 154.008 (4.00 to 6.00)3.867 (0.50 to 6.00)4.333 (4.00 to 4.42)2.167 (1.95 to 5.75)6.033 (6.00 to 6.07)6.050 (4.08 to 6.07)5.933 (NA to NA)
PrimaryTerminal Elimination Half-life (t1/2) After Multiple Doses of Gilteritinib

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose
Reported as:
Mean · hours
Terminal Elimination Half-life (t1/2) After Multiple Doses of Gilteritinib
hoursGilteritinib 20 mg in Escalation PhaseGilteritinib 40 mg in Escalation PhaseGilteritinib 80 mg in Escalation PhaseGilteritinib 120 mg in Escalation PhaseGilteritinib 200 mg in Escalation PhaseGilteritinib 300 mg in Escalation PhaseGilteritinib 450 mg in Escalation Phase
Terminal Elimination Half-life (t1/2) After Multiple Doses of Gilteritinib62.14 ± 17.88151.8 ± 129.286.11 ± 24.0845.85 ± 18.83141.9 ± 61.51142.2 ± 55.04—
PrimaryAccumulation Ratio After Multiple Doses of Gilteritinib

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose
Reported as:
Mean · ratio
Accumulation Ratio After Multiple Doses of Gilteritinib
ratioGilteritinib 20 mg in Escalation PhaseGilteritinib 40 mg in Escalation PhaseGilteritinib 80 mg in Escalation PhaseGilteritinib 120 mg in Escalation PhaseGilteritinib 200 mg in Escalation PhaseGilteritinib 300 mg in Escalation PhaseGilteritinib 450 mg in Escalation Phase
Accumulation Ratio After Multiple Doses of Gilteritinib4.259 ± 1.0699.640 ± 7.7545.693 ± 1.4423.290 ± 1.1189.041 ± 3.6939.057 ± 3.303—
SecondaryPercentage of Participants With Complete Remission (CR) During the First 2 Cycles

CR was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CR when they had bone marrow regenerating normal hematopoietic cells, achieved a morphologic leukemia-free state, had an absolute neutrophil count (ANC) \> 1 x 10\^9/L, platelet count ≥ 100 x 10\^9/L, normal marrow differential with \< 5% blasts, had been red blood cell (RBC) and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion), had no presence of Auer rods and no evidence of extramedullary leukemia, and blast counts in peripheral blood had been ≤ 2%. Exact 95% confidence interval was estimated using binomial distribution.

Time frame:
During the first 2 cycles (56 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission (CR) During the First 2 Cycles
percentage of participantsGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation Positive0 (NA to NA)0 (NA to NA)8.3 (0.2 to 38.5)3.6 (0.4 to 12.3)3.4 (0.7 to 9.5)10 (0.3 to 44.5)0 (NA to NA)
FLT3 Mutation Negative50.0 (1.3 to 98.7)0 (NA to NA)0 (NA to NA)0 (NA to NA)0 (NA to NA)0 (NA to NA)0 (NA to NA)
All Participants6.3 (0.2 to 30.2)0 (NA to NA)4.2 (0.1 to 21.1)2.9 (0.3 to 9.9)3.0 (0.6 to 8.5)5.0 (0.1 to 24.9)0 (NA to NA)
SecondaryPercentage of Participants With CR During Treatment

CR was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CR when they had bone marrow regenerating normal hematopoietic cells, achieved a morphologic leukemia-free state, had an absolute neutrophil count (ANC) \> 1 x 10\^9/L, platelet count ≥ 100 x 10\^9/L, normal marrow differential with \< 5% blasts, had been red blood cell (RBC) and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion), had no presence of Auer rods and no evidence of extramedullary leukemia, and blast counts in peripheral blood had been ≤ 2%. Exact 95% confidence interval was estimated using binomial distribution.

Time frame:
Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Number · percentage of participants
Percentage of Participants With CR During Treatment
percentage of participantsGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation Positive0 (NA to NA)0 (NA to NA)16.7 (2.1 to 48.4)12.5 (5.2 to 24.1)11.2 (5.5 to 19.7)10.0 (0.3 to 44.5)0 (NA to NA)
FLT3 Mutation Negative50.0 (1.3 to 98.7)0 (NA to NA)0 (NA to NA)0 (NA to NA)0 (NA to NA)0 (NA to NA)0 (NA to NA)
All Participants6.3 (0.2 to 30.2)0 (NA to NA)8.3 (1.0 to 27.0)10.0 (4.1 to 19.5)10.0 (4.9 to 17.6)5.0 (0.1 to 54.9)0 (NA to NA)
SecondaryPercentage of Participants With CR With Incomplete Platelet Recovery (CRp)

CRp was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CRp when they achieved CR except for incomplete platelet recovery (\< 100 x 10\^9/L). Exact 95% confidence interval was estimated using the binomial distribution.

Time frame:
Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Number · percentage of participants
Percentage of Participants With CR With Incomplete Platelet Recovery (CRp)
percentage of participantsGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation Positive0 (NA to NA)0 (NA to NA)0 (NA to NA)3.6 (0.4 to 12.3)9.0 (4.0 to 16.9)10.0 (0.3 to 44.5)0 (NA to NA)
FLT3 Mutation Negative0 (NA to NA)0 (NA to NA)0 (NA to NA)0 (NA to NA)0 (NA to NA)0 (NA to NA)0 (NA to NA)
All Participants0 (NA to NA)0 (NA to NA)0 (NA to NA)2.9 (0.3 to 9.9)8.0 (3.5 to 15.2)5.0 (0.1 to 24.9)0 (NA to NA)
SecondaryPercentage of Participants With CR With Incomplete Hematological Recovery (CRi)

CRi was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CRi when they fulfilled all the criteria for CR except for incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence were not required. Exact 95% confidence interval was estimated using the binomial distribution.

Time frame:
Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Number · percentage of participants
Percentage of Participants With CR With Incomplete Hematological Recovery (CRi)
percentage of participantsGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation Positive7.1 (0.2 to 33.9)0 (NA to NA)25.0 (5.5 to 57.2)30.4 (18.8 to 44.1)20.2 (12.4 to 30.1)10.0 (0.3 to 44.5)0 (NA to NA)
FLT3 Mutation Negative0 (NA to NA)0 (NA to NA)16.7 (2.1 to 48.4)7.1 (0.2 to 33.9)9.1 (0.2 to 41.3)0 (NA to NA)0 (NA to NA)
All Participants6.3 (0.2 to 30.2)0 (NA to NA)20.8 (7.1 to 42.2)25.7 (16.0 to 37.6)19.0 (11.8 to 28.1)5.0 (0.1 to 24.9)0 (NA to NA)
SecondaryPercentage of Participants With Complete Remission With Partial Hematologic Recovery (CRh)

CRh was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CRh when they could not be classified as being in CR and had bone marrow blasts \< 5% and partial hematologic recovery ANC \>= 0.5 x 10\^9/L and platelets \>= 50 x 10\^9/L. There should not be evidence of extramedullary leukemia. Exact 95% confidence interval was estimated using the binomial distribution. CRh was calculated only for participants who were FLT3 mutation positive.

Time frame:
Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission With Partial Hematologic Recovery (CRh)
percentage of participantsGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
Percentage of Participants With Complete Remission With Partial Hematologic Recovery (CRh)7.1 (0.2 to 33.9)0 (0 to 0)8.3 (0.2 to 38.5)10.7 (4.0 to 21.9)7.9 (3.2 to 15.5)20.0 (2.5 to 55.6)0 (0 to 0)
SecondaryPercentage of Participants With Composite CR (CRc)

CRc was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in CRc when they had achieved either CR, complete remission with incomplete platelet recovery (CRp, defined as had achieved CR except for incomplete platelet recovery (\< 100 x 10\^9/L) or complete remission with incomplete hematologic recovery (CRi, defined as had fulfilled all the criteria for CR except for incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery; RBC platelet transfusion independence not required). Exact 95% confidence interval was estimated using the binomial distribution.

Time frame:
Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Composite CR (CRc)
percentage of participantsGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation Positive7.1 (0.2 to 33.9)0 (NA to NA)41.7 (15.2 to 72.3)46.4 (33.0 to 60.3)40.4 (30.2 to 51.4)30.0 (6.7 to 65.2)0 (NA to NA)
FLT3 Mutation Negative50.0 (1.3 to 98.7)0 (NA to NA)16.7 (2.1 to 48.4)7.1 (0.2 to 33.9)9.1 (0.2 to 41.3)0 (NA to NA)0 (NA to NA)
All Participants12.5 (1.6 to 38.3)0 (NA to NA)29.2 (12.6 to 51.1)38.6 (27.2 to 51.0)37.0 (27.6 to 47.2)15.0 (3.2 to 37.9)0 (NA to NA)
SecondaryPercentage of Participants With Partial Remission (PR)

PR was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). Participants were classified as being in PR when they had bone marrow regenerating normal hematopoietic cells with evidence of peripheral recovery with no (or only a few regenerating) circulating blasts and with a decrease of at least 50% in the percentage of blasts in the bone marrow aspirate with the total marrow blasts between 5% and 25%. A value of less or equal than 5% blasts was also considered a PR if Auer rods were present. There should be no evidence of extramedullary leukemia. Exact 95% confidence interval was estimated using the binomial distribution.

Time frame:
Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Partial Remission (PR)
percentage of participantsGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation Positive7.1 (0.2 to 33.9)37.5 (8.5 to 75.5)25.0 (5.5 to 57.2)7.1 (2.0 to 17.3)7.9 (3.2 to 15.5)30.0 (6.7 to 65.2)50.0 (1.3 to 98.7)
FLT3 Mutation Negative0 (NA to NA)0 (NA to NA)0 (NA to NA)7.1 (0.2 to 33.9)9.1 (0.2 to 41.3)0 (NA to NA)0 (NA to NA)
All Participants6.3 (0.2 to 30.2)18.8 (4.0 to 45.6)12.5 (2.7 to 32.4)7.1 (2.4 to 15.9)8.0 (3.5 to 15.2)15.0 (3.2 to 37.9)33.3 (0.8 to 90.6)
SecondaryPercentage of Participants With Best Response

Best response was defined according to modified Cheson criteria (2003), using centrally evaluated myeloblast counts from bone marrow aspirate/biopsy assessments and centrally evaluated hematology results; if neither central bone marrow aspirate nor biopsy was available, myeloblast was imputed with locally evaluated bone marrow aspirate/biopsy assessments (derived response). BR was defined as the best measured response for all visits (in the order of CR, CRp, CRi, and PR) post-treatment. Participants who achieved the best response of CR, CRp, CRi or PR were classified as responders. Participants who did not achieve at least PR were considered as non-responders. Exact 95% confidence interval was estimated using the binomial distribution.

Time frame:
Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Response
percentage of participantsGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation Positive14.3 (1.8 to 42.8)37.5 (8.5 to 75.5)66.7 (34.9 to 90.1)53.6 (39.7 to 67.0)48.3 (37.6 to 59.2)60.0 (26.2 to 87.8)50.0 (1.3 to 98.7)
FLT3 Mutation Negative50.0 (1.3 to 98.7)0 (NA to NA)16.7 (2.1 to 48.4)14.3 (1.8 to 42.8)18.2 (2.3 to 51.8)0 (NA to NA)0 (NA to NA)
All Participants18.8 (4.0 to 45.6)18.8 (4.0 to 45.6)41.7 (22.1 to 63.4)45.7 (33.7 to 58.1)45.0 (35.0 to 55.3)30.0 (11.9 to 54.3)33.3 (0.8 to 90.6)
SecondaryPercentage of Participants With Complete Remission and Complete Remission With Partial Hematologic Recovery (CR/CRh)

Participants with CR/CRh were defined as participants who achieved either CR or CRh. Participants with CR had bone marrow regenerating normal hematopoietic cells, achieved a morphologic leukemia-free state, had an ANC \> 1 x 10\^9/L, platelet count ≥ 100 x 10\^9/L, and normal marrow differential with \< 5% blasts, had been RBC and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion). Also, there had been no presence of Auer rods, no evidence of extramedullary leukemia, and blast counts in peripheral blood had been ≤ 2%. Participants with CRh could not be classified as being in CR and had bone marrow blasts \< 5%, partial hematologic recovery ANC \>= 0.5 x 10\^9/L and platelets \>= 50 x 10\^9/L. There should not be evidence of extramedullary leukemia. Exact 95% confidence interval was estimated using the binomial distribution. CR/CRh was calculated only for participants who were FLT3 mutation positive.

Time frame:
Up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission and Complete Remission With Partial Hematologic Recovery (CR/CRh)
percentage of participantsGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
Percentage of Participants With Complete Remission and Complete Remission With Partial Hematologic Recovery (CR/CRh)7.1 (0.2 to 33.9)0 (NA to NA)25.0 (5.5 to 57.2)23.2 (13.0 to 36.4)19.1 (11.5 to 28.8)30.0 (6.7 to 65.2)0 (NA to NA)
SecondaryDuration of CR (DCR)

DCR was defined as the time from the date of first CR until the date of documented relapse for participants who achieved CR. Participants who died without report of relapse were considered non-events and censored at their last relapse-free disease assessment date. Other participants who did not relapse on study were considered non-events and censored at the last relapse-free disease assessment date. DCR was calculated using Kaplan-Meier method and therefore data are estimated.

Time frame:
From date of remission until end of study (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Median · days
Duration of CR (DCR)
daysGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation Positive——NA (NA to NA)NA (86.0 to NA)419.0 (64.0 to NA)NA (NA to NA)—
FLT3 Mutation NegativeNA (NA to NA)——————
All ParticipantsNA (NA to NA)—NA (NA to NA)NA (86.0 to NA)419.0 (64.0 to NA)NA (NA to NA)—
SecondaryDuration of CRp (DCRp)

DCRp was defined as the time from the date of first CRp until the date of documented relapse for participants who achieved CRp. Participants who died without report of relapse were considered non-events and censored at their last relapse-free disease assessment date. Other participants who did not relapse on study were considered non-events and censored at the last relapse-free disease assessment date. DCRp was calculated using Kaplan-Meier method and therefore data are estimated.

Time frame:
From date of remission until end of study (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Median · days
Duration of CRp (DCRp)
daysGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation Positive——NA (NA to NA)NA (57.0 to NA)450.0 (43.0 to NA)NA (NA to NA)—
All Participants——NA (NA to NA)NA (57.0 to NA)450.0 (43.0 to NA)NA (NA to NA)—
SecondaryDuration of CRi (DCRi)

DCRi was defined as the time from the date of first CRi until the date of documented relapse for participants who achieved CRi. Participants who died without report of relapse and participants who did not relapse were considered non-events and censored at the last relapse-free disease assessment date. DCRi was calculated using Kaplan-Meier method and therefore data are estimated.

Time frame:
From date of remission until end of study (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Median · days
Duration of CRi (DCRi)
daysGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation PositiveNA (NA to NA)—NA (79.0 to NA)120.0 (56.0 to 383.0)191.0 (57.0 to 420.0)NA (NA to NA)—
FLT3 Mutation Negative——41.0 (22.0 to 60.0)99.0 (NA to NA)———
All ParticipantsNA (NA to NA)—79.0 (22.0 to NA)120.0 (58.0 to 383.0)191.0 (57.0 to 420.0)NA (NA to NA)—
SecondaryDuration of CRh (DCRh)

DCRh was defined as the time from the date of first CRh until the date of documented relapse for participants who achieved CRh but did not have a best response of CR. Participants who died without report of relapse and participants who did not relapse were considered non-events and censored at the last relapse-free disease assessment date. DCRh was calculated using Kaplan-Meier method and therefore data are estimated. DCRh was calculated only for participants who were FLT3 mutation positive.

Time frame:
From date of remission until end of study (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Median · days
Duration of CRh (DCRh)
daysGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
Duration of CRh (DCRh)NA (NA to NA)—NA (NA to NA)64.0 (18.0 to 85.0)101.0 (29.0 to NA)NA (NA to NA)—
SecondaryDuration of CRc (DCRc)

DCRc was defined as the time from the date of first CRc until the date of documented relapse for participants who achieved CRc. Participants who died without report of relapse and participants who did not relapse were considered non-events and censored at the last relapse-free disease assessment date. DCRc was calculated using Kaplan-Meier method and therefore data are estimated.

Time frame:
From date of remission until end of study (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Median · days
Duration of CRc (DCRc)
daysGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation PositiveNA (NA to NA)—NA (79.0 to NA)98.0 (57.0 to 307.0)191.0 (101.0 to 465.0)NA (NA to NA)—
FLT3 Mutation NegativeNA (NA to NA)—41.0 (22.0 to 60.0)99.0 (NA to NA)NA (NA to NA)——
All ParticipantsNA (NA to NA)—79.0 (22.0 to NA)99.0 (58.0 to 307.0)191.0 (101.0 to 465.0)NA (NA to NA)—
SecondaryDuration of CR/CRh (DCRCRh)

DCRCRh was defined as the time from the date of first DCRCRh until the date of documented relapse for participants who achieved CR or CRh. For participants who achieved both CR and CRh, the first CR date or CRh date, whichever occurred first, was used. Participants who died without report of relapse and participants who did not relapse were considered non-events and censored at the last relapse-free disease assessment date. DCRCRh was calculated using Kaplan-Meier method and therefore data are estimated. DCRCRh was calculated only for participants who were FLT3 mutation positive.

Time frame:
From date of remission until end of study (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Median · days
Duration of CR/CRh (DCRCRh)
daysGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
Duration of CR/CRh (DCRCRh)NA (NA to NA)—NA (NA to NA)307.0 (56.0 to NA)308.0 (101.0 to NA)NA (NA to NA)—
SecondaryDuration of Response

Duration of response was defined as the time from the date of either first CRc or PR until the date of documented relapse of any type for participants who achieved CRc or PR. Participants who died without report of relapse were considered non-events and censored at their last relapse-free disease assessment date. Other participants who did not relapse on study are considered non-events and censored at the last relapse-free assessment date. Duration of response was calculated using Kaplan-Meier method and therefore data are estimated.

Time frame:
From date of remission until end of study (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Median · days
Duration of Response
daysGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation PositiveNA (NA to NA)NA (NA to NA)88.0 (9.0 to NA)141.0 (58.0 to 383.0)220.0 (111.0 to 482.0)59.0 (15.0 to 59.0)NA (NA to NA)
FLT3 Mutation NegativeNA (NA to NA)—41.0 (22.0 to 60.0)109.5 (99.0 to 120.0)85.0 (NA to NA)——
All ParticipantsNA (NA to NA)NA (NA to NA)79.0 (9.0 to NA)126.0 (58.0 to 307.0)220.0 (85.0 to 482.0)59.0 (15.0 to 59.0)NA (NA to NA)
SecondaryTime to CR (TTCR)

TTCR was defined as the time from the first dose of study drug until the date of first CR.

Time frame:
From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Median · days
Time to CR (TTCR)
daysGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation Positive——171.5 (28 to 315)141.0 (29 to 364)93.0 (27 to 225)56.0 (56 to 56)—
FLT3 Mutation Negative30.0 (30 to 30)——————
All Participants30.0 (30 to 30)—171.5 (28 to 315)141.0 (29 to 364)93.0 (27 to 225)56.0 (56 to 56)—
SecondaryTime to CRp (TTCRp)

TTCRp was defined as the time from the first dose of study drug until the date of first CRp. TTCRp was evaluated for participants who achieved CRp.

Time frame:
From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Median · days
Time to CRp (TTCRp)
daysGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation Positive——140.0 (140 to 140)195.0 (30 to 418)84.5 (28 to 392)29.0 (28 to 30)—
All Participants——140.0 (140 to 140)195.0 (30 to 418)84.5 (28 to 392)29.0 (28 to 30)—
SecondaryTime to CRi (TTCRi)

TTCRi was defined as the time from the first dose of study drug until the date of first CRi. TTCRi was evaluated for participants who achieved CRi.

Time frame:
From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Median · days
Time to CRi (TTCRi)
daysGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation Positive57.0 (57 to 57)—57.0 (31 to 70)57.0 (26 to 170)39.5 (26 to 133)28.0 (28 to 28)—
FLT3 Mutation Negative——71.5 (71 to 72)30.0 (30 to 30)30.0 (30 to 30)——
All Participants57.0 (57 to 57)—64.0 (31 to 72)43.5 (26 to 170)35.0 (26 to 133)28.0 (28 to 28)—
SecondaryTime to First CR/CRh (TTFCRCRh)

TTFCRCRh was defined as the time from the first dose of study drug until the date of first either CR or CRh. TTFCRCRh was evaluated for participants who achieved CR or CRh. For participants who achieve both CR and CRh, the first CR date or CRh date, whichever occurs first was used. TTFCRCRh was calculated only for participants who were FLT3 mutation positive.

Time frame:
From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Median · days
Time to First CR/CRh (TTFCRCRh)
daysGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
Time to First CR/CRh (TTFCRCRh)57.0 (57 to 57)—57.0 (28 to 140)59.0 (29 to 280)57.0 (27 to 245)28.0 (28 to 30)—
SecondaryTime to Best CR/CRh (TTBCRCRh)

TTBCRCRh was defined as the time from the first dose of study drug until the first date that the best response of CR or CRh was achieved. TTBCRCRh was evaluated for participants who achieved CR or CRh. For participants who achieve both CR and CRh, the first CR date was used. TTBCRCRh was calculated only for participants who were FLT3 mutation positive.

Time frame:
From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Median · days
Time to Best CR/CRh (TTBCRCRh)
daysGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
Time to Best CR/CRh (TTBCRCRh)57.0 (57 to 57)—57.0 (28 to 315)63.0 (29 to 364)88.0 (27 to 245)30.0 (28 to 56)—
SecondaryTime to CRc (TTCRc)

TTCRc was defined as the time from the first dose of study drug until the date of first CRc. TTCRc was evaluated for participants who achieved CRc.

Time frame:
From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Median · days
Time to CRc (TTCRc)
daysGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation Positive57.0 (57 to 57)—56.0 (28 to 64)30.0 (26 to 211)31.5 (26 to 197)28.0 (28 to 30)—
FLT3 Mutation Negative30.0 (30 to 30)—71.5 (71 to 72)30.0 (30 to 30)30.0 (30 to 30)——
All Participants43.5 (30 to 57)—57.0 (28 to 72)30.0 (26 to 211)31.0 (26 to 197)28.0 (28 to 30)—
SecondaryTime to Response (TTR)

TTR was defined as the time from the first dose of study drug until the date of either first CRc or PR. TTR was evaluated for participants who achieved CRc or PR.

Time frame:
From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Median · days
Time to Response (TTR)
daysGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation Positive61.5 (29 to 94)57.0 (31 to 64)31.0 (28 to 59)29.0 (26 to 211)29.0 (26 to 197)28.0 (26 to 61)31.0 (31 to 31)
FLT3 Mutation Negative30.0 (30 to 30)—71.5 (71 to 72)29.5 (29 to 30)29.5 (29 to 30)——
All Participants30.0 (29 to 94)57.0 (31 to 64)43.5 (28 to 72)29.0 (26 to 211)29.0 (26 to 197)28.0 (26 to 61)31.0 (31 to 31)
SecondaryTime to Best Response (TTBR)

TTBR was defined as the time from the first dose of study drug until the first disease assessment date when participant achieved best response. TTBR was evaluated in participants who achieved best response of CR, CRp, CRi, or PR.

Time frame:
From first dose of study drug up to end of treatment (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days)
Reported as:
Median · days
Time to Best Response (TTBR)
daysGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation Positive75.5 (57 to 94)57.0 (31 to 64)44.0 (28 to 315)43.5 (26 to 364)57.0 (26 to 245)29.0 (26 to 61)31.0 (31 to 31)
FLT3 Mutation Negative30.0 (30 to 30)—71.5 (71 to 72)29.5 (29 to 30)29.5 (29 to 30)——
All Participants57.0 (30 to 94)57.0 (31 to 64)58.0 (28 to 315)30.0 (26 to 364)56.0 (26 to 245)29.0 (26 to 61)31.0 (31 to 31)
SecondaryOverall Survival (OS)

The time from the date of first dose of study drug until the date of death from any cause. For a participant who was not known to have died by the end of study follow-up, OS was censored at the date of last contact. OS was calculated using Kaplan-Meier method and therefore data are estimated.

Time frame:
From first dose of study drug up to end of study (median time on study was 157.0 days, minimum of 5 days and maximum of 1320 days)
Reported as:
Median · days
Overall Survival (OS)
daysGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation Positive123.0 (17.0 to 267.0)199.5 (56.0 to 905.0)197.5 (61.0 to 329.0)246.0 (190.0 to 309.0)214.0 (126.0 to 264.0)157.0 (20.0 to 218.0)204.0 (51.0 to 357.0)
FLT3 Mutation NegativeNA (227.0 to NA)71.5 (5.0 to 180.0)136.0 (14.0 to 314.0)144.0 (83.0 to 195.0)67.0 (21.0 to 336.0)68.0 (8.0 to 249.0)89.0 (NA to NA)
All Participants149.5 (31.0 to 267.0)95.0 (55.0 to 195.0)154.0 (74.0 to 299.0)216.0 (161.0 to 285.0)176.0 (124.0 to 253.0)128.5 (36.0 to 199.0)89.0 (51.0 to 357.0)
SecondaryEvent Free Survival (EFS)

EFS was defined as the time from the date of first dose of study drug until the date of documented relapse, treatment failure or death from any cause, whichever occurred first. For a participant with none of these events, EFS was censored at the date of last relapse-free disease assessment. A participant without post-treatment disease assessment was censored at randomization date. Treatment failure included those participants who discontinued the treatment due to "progressive disease" or "lack of efficacy" without a previous response of CR, CRp, CRi or PR. Treatment failure date referred to the start of new anti-leukemia therapy or the last treatment evaluation date when new anti-leukemia therapy date was not available. For participants who were censored, last relapse-free disease assessment date referred to the participant's last disease assessment date. EFS was calculated using Kaplan-Meier method and therefore data are estimated.

Time frame:
From first dose of study drug up to end of study (median time on study was 157.0 days, minimum of 5 days and maximum of 1320 days)
Reported as:
Median · days
Event Free Survival (EFS)
daysGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation Positive52.0 (14.0 to 88.0)109.0 (29.0 to 357.0)93.5 (61.0 to 127.0)112.0 (92.0 to 143.0)121.0 (92.0 to 155.0)85.0 (11.0 to 157.0)86.0 (51.0 to 121.0)
FLT3 Mutation Negative58.0 (NA to NA)39.0 (5.0 to 67.0)74.0 (12.0 to 131.0)85.5 (37.0 to 126.0)45.0 (21.0 to 113.0)43.0 (8.0 to 83.0)71.0 (NA to NA)
All Participants58.0 (19.0 to 88.0)55.5 (38.0 to 92.0)76.0 (61.0 to 119.0)108.0 (90.0 to 126.0)118.0 (88.0 to 140.0)65.0 (20.0 to 100.0)71.0 (51.0 to 121.0)
SecondaryLeukemia Free Survival (LFS)

LFS was defined as the time from the date of first CRc until the date of documented relapse or death for participants who achieved CRc. For a participant who was not known to have relapsed or died, LFS was censored on the date of last relapse-free disease assessment date. LFS was calculated using Kaplan-Meier method and therefore data are estimated.

Time frame:
From first dose of study drug up to end of study (median time on study was 157.0 days, minimum of 5 days and maximum of 1320 days)
Reported as:
Median · days
Leukemia Free Survival (LFS)
daysGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation Positive242.0 (NA to NA)—98.0 (56.0 to 1126.0)98.0 (58.0 to 187.0)146.0 (47.0 to 247.0)296.0 (130.0 to 462.0)—
FLT3 Mutation NegativeNA (NA to NA)—41.0 (22.0 to 60.0)99.0 (NA to NA)38.0 (NA to NA)——
All Participants242.0 (NA to NA)—79.0 (22.0 to 1126.0)98.0 (58.0 to 187.0)146.0 (45.0 to 247.0)296.0 (130.0 to 462.0)—
SecondaryPercentage of Participants Who Achieved Transfusion Conversion

Participants who achieved transfusion conversion were defined as the number of participants who were transfusion dependent at baseline period but became transfusion independent at post-baseline period divided by the total number of participants who were transfusion dependent at baseline period. Participants were considered baseline transfusion dependent if there were RBC or platelet transfusions within the baseline period. Participants were considered post-baseline transfusion independent if they were on treatment \>=84 days, and if there was one consecutive 56 days without any RBC or platelet transfusion within post-baseline period. If participants were on treatment \>28 days but \<84 days, and there was no RBC or platelet transfusion within post-baseline period, or on treatment \<=28 days, post-baseline transfusion status was not evaluable. Exact 95% confidence interval was estimated using the binomial distribution.

Time frame:
Baseline (28 days prior to first dose until 28 days after the first dose) and postbaseline (from 29 days after first dose date until last dose date); median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Transfusion Conversion
percentage of participantsGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation Positive0 (NA to NA)0 (NA to NA)37.5 (8.5 to 75.5)27.5 (14.6 to 43.9)40.4 (27.6 to 54.2)NA (NA to NA)NA (NA to NA)
FLT3 Mutation NegativeNA (NA to NA)NA (NA to NA)12.5 (0.3 to 52.7)22.2 (2.8 to 60.0)33.3 (4.3 to 77.7)NA (NA to NA)NA (NA to NA)
All ParticipantsNA (NA to NA)NA (NA to NA)25.0 (7.3 to 52.4)26.5 (14.9 to 41.1)39.7 (27.6 to 52.8)NA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants Who Achieved Transfusion Maintenance

Participants who achieved transfusion maintenance were defined as the number of participants who were transfusion independent at baseline period and still maintained transfusion independent at post-baseline period divided by the total number of participants who were transfusion independent at baseline period.

Time frame:
Baseline (28 days prior to first dose until 28 days after the first dose) and postbaseline (from 29 days after first dose date until last dose date); median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Transfusion Maintenance
percentage of participantsGilteritinib 20 mgGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgGilteritinib 300 mgGilteritinib 450 mg
FLT3 Mutation Positive——100.0 (2.5 to 100)75.0 (19.4 to 99.4)80.0 (44.4 to 97.5)—100.0 (2.5 to 100.0)
FLT3 Mutation Negative———33.3 (0.8 to 90.6)———
All Participants——100.0 (2.5 to 100.0)57.1 (18.4 to 90.1)80.0 (44.4 to 97.5)—100.0 (2.5 to 100.0)
SecondaryAUC24 of Gilteritinib in Co-administration With Voriconazole

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Cycle 1 Day 15 and Cycle 2 Day 1: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (gilteritinib)
Reported as:
Mean · ng*h/mL
AUC24 of Gilteritinib in Co-administration With Voriconazole
ng*h/mLGilteritinib 20 mg in Expansion Phase
AUC24 of Gilteritinib in Co-administration With Voriconazole919.3 ± NA
SecondaryCmax of Gilteritinib in Co-administration With Voriconazole

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Cycle 1 Day 15 and Cycle 2 Day 1: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (gilteritinib)
Reported as:
Mean · ng/mL
Cmax of Gilteritinib in Co-administration With Voriconazole
ng/mLGilteritinib 20 mg in Expansion Phase
Cmax of Gilteritinib in Co-administration With Voriconazole63.79 ± NA
SecondaryAUClast of Gilteritinib in Co-administration With Voriconazole

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Cycle 1 Day 15 and Cycle 2 Day 1: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (gilteritinib)
Reported as:
Mean · ng*h/mL
AUClast of Gilteritinib in Co-administration With Voriconazole
ng*h/mLGilteritinib 20 mg in Expansion Phase
AUClast of Gilteritinib in Co-administration With Voriconazole919.3 ± NA
SecondaryTmax of Gilteritinib in Co-administration With Voriconazole

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Cycle 1 Day 15 and Cycle 2 Day 1: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (gilteritinib)
Reported as:
Median · hours
Tmax of Gilteritinib in Co-administration With Voriconazole
hoursGilteritinib 20 mg in Expansion Phase
Tmax of Gilteritinib in Co-administration With Voriconazole2.08 (2.08 to 2.08)
SecondaryAUC24 of Midazolam Administered With and Without Gilteritinib

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)
Reported as:
Mean · ng*h/mL
AUC24 of Midazolam Administered With and Without Gilteritinib
ng*h/mLGilteritinib 300 mg in Expansion Phase
Midazolam Alone (Day -1)66.55 ± 57.70
Midazolam + Gilteritinib (Cycle 1 Day 15)81.56 ± 65.84
Statistical analysis
  • Gilteritinib 300 mg in Expansion Phase · Geometric ls mean ratio: 109.46 · 90% CI 49.82 to 240.48
SecondaryAUC24 of Metabolite 1-Hydroxymidazolam After Administration of Midazolam With and Without Gilteritinib

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)
Reported as:
Mean · ng*h/mL
AUC24 of Metabolite 1-Hydroxymidazolam After Administration of Midazolam With and Without Gilteritinib
ng*h/mLGilteritinib 300 mg in Expansion Phase
Midazolam Alone (Day -1)20.44 ± 24.80
Midazolam + Gilteritinib (Cycle 1 Day 15)23.10 ± 21.64
Statistical analysis
  • Gilteritinib 300 mg in Expansion Phase · Geometric ls mean ratio: 149.90 · 90% CI 74.88 to 300.06
SecondaryCmax of Midazolam Administered With and Without Gilteritinib

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)
Reported as:
Mean · ng/mL
Cmax of Midazolam Administered With and Without Gilteritinib
ng/mLGilteritinib 300 mg in Expansion Phase
Midazolam Alone (Day -1)14.68 ± 8.923
Midazolam + Gilteritinib (Cycle 1 Day 15)18.45 ± 9.452
Statistical analysis
  • Gilteritinib 300 mg in Expansion Phase · Geometric ls mean ratio: 111.64 · 90% CI 69.54 to 179.25
SecondaryCmax of 1-Hydroxymidazolam After Administration of Midazolam With and Without Gilteritinib

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)
Reported as:
Mean · ng/mL
Cmax of 1-Hydroxymidazolam After Administration of Midazolam With and Without Gilteritinib
ng/mLGilteritinib 300 mg in Expansion Phase
Midazolam Alone (Day -1)4.562 ± 2.858
Midazolam + Gilteritinib (Cycle 1 Day 15)5.053 ± 3.158
Statistical analysis
  • Gilteritinib 300 mg in Expansion Phase · Geometric ls mean ratio: 123.47 · 90% CI 72.41 to 210.52
SecondaryAUClast of Midazolam Administered With and Without Gilteritinib

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)
Reported as:
Mean · ng*h/mL
AUClast of Midazolam Administered With and Without Gilteritinib
ng*h/mLGilteritinib 300 mg in Expansion Phase
Midazolam Alone (Day -1)59.48 ± 59.49
Midazolam + Gilteritinib (Cycle 1 Day 15)82.44 ± 64.25
SecondaryAUClast of 1-Hydroxymidazolam After Administration of Midazolam With and Without Gilteritinib

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)
Reported as:
Mean · ng*h/mL
AUClast of 1-Hydroxymidazolam After Administration of Midazolam With and Without Gilteritinib
ng*h/mLGilteritinib 300 mg in Expansion Phase
Midazolam Alone (Day -1)17.05 ± 24.70
Midazolam + Gilteritinib (Cycle 1 Day 15)23.58 ± 22.07
SecondaryTmax of Midazolam Administered With and Without Gilteritinib

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)
Reported as:
Median · hours
Tmax of Midazolam Administered With and Without Gilteritinib
hoursGilteritinib 300 mg in Expansion Phase
Midazolam Alone (Day -1)0.5000 (0.367 to 2.00)
Midazolam + Gilteritinib (Cycle 1 Day 15)1.00 (0.317 to 4.13)
SecondaryTmax of 1-Hydroxymidazolam After Administration of Midazolam With and Without Gilteritinib

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Day -1 and cycle 1 day 15: predose, 0.5, 1, 2, 4, 6, 24 hours postdose (midazolam)
Reported as:
Median · hours
Tmax of 1-Hydroxymidazolam After Administration of Midazolam With and Without Gilteritinib
hoursGilteritinib 300 mg in Expansion Phase
Midazolam Alone (Day -1)0.5583 (0.483 to 2.00)
Midazolam + Gilteritinib (Cycle 1 Day 15)1.00 (0.317 to 4.13)
SecondaryArea Under the Concentration-time Curve From the Time of Dosing Extrapolated to Time Infinity (AUCinf) of Cephalexin Administered With and Without Gilteritinib

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Day -1 and cycle 1 day 15: predose, 0.5, 1, 1.5, 2, 3, 4, 6, 24 hours postdose (cephalexin)
Reported as:
Mean · ng*h/mL
Area Under the Concentration-time Curve From the Time of Dosing Extrapolated to Time Infinity (AUCinf) of Cephalexin Administered With and Without Gilteritinib
ng*h/mLGilteritinib 200 mg in Expansion Phase
Cephalexin Alone (Day -1)57650 ± 20386
Cephalexin + Gilteritinib (Cycle 1 Day 15)51873 ± 18819
Statistical analysis
  • Gilteritinib 200 mg in Expansion Phase · Geometric ls mean ratio: 93.96 · 90% CI 75.29 to 117.26
SecondaryCmax of Cephalexin Administered With and Without Gilteritinib

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Day -1 and cycle 1 day 15: predose, 0.5, 1, 1.5, 2, 3, 4, 6, 24 hours postdose (cephalexin)
Reported as:
Mean · ng/mL
Cmax of Cephalexin Administered With and Without Gilteritinib
ng/mLGilteritinib 200 mg in Expansion Phase
Cephalexin Alone (Day -1)17688 ± 6680
Cephalexin + Gilteritinib (Cycle 1 day 15)16075 ± 4606
Statistical analysis
  • Gilteritinib 200 mg in Expansion Phase · Geometric ls mean ratio: 91.46 · 90% CI 74.60 to 112.12
SecondaryAUClast of Cephalexin Administered With and Without Gilteritinib

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Day -1 and cycle 1 day 15: predose, 0.5, 1, 1.5, 2, 3, 4, 6, 24 hours postdose (cephalexin)
Reported as:
Mean · ng*h/mL
AUClast of Cephalexin Administered With and Without Gilteritinib
ng*h/mLGilteritinib 200 mg in Expansion Phase
Cephalexin Alone (Day -1)53183 ± 26877
Cephalexin + Gilteritinib (Cycle 1 Day 15)54963 ± 29531
Statistical analysis
  • Gilteritinib 200 mg in Expansion Phase · Geometric ls mean ratio: 97.71 · 90% CI 74.19 to 128.70
SecondaryTmax of Cephalexin Administered With and Without Gilteritinib

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Day -1 and cycle 1 day 15: predose, 0.5, 1, 1.5, 2, 3, 4, 6, 24 hours postdose (cephalexin)
Reported as:
Median · hours
Tmax of Cephalexin Administered With and Without Gilteritinib
hoursGilteritinib 200 mg in Expansion Phase
Cephalexin Alone (Day -1)1.500 (1.00 to 4.02)
Cephalexin + Gilteritinib (Cycle 1 Day 15)1.483 (1.00 to 5.88)
SecondaryT1/2 of Cephalexin Administered With and Without Gilteritinib

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Day -1 and cycle 1 day 15: predose, 0.5, 1, 1.5, 2, 3, 4, 6, 24 hours postdose (cephalexin)
Reported as:
Mean · hours
T1/2 of Cephalexin Administered With and Without Gilteritinib
hoursGilteritinib 200 mg in Expansion Phase
Cephalexin Alone (Day -1)1.822 ± 0.5914
Cephalexin + Gilteritinib (Cycle 1 Day 15)1.827 ± 0.7175
SecondaryApparent Total Systemic Clearance After Single or Multiple Extravascular Dosing (CL/F) of Cephalexin Administered With and Without Gilteritinib

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Day -1 and cycle 1 day 15: predose, 0.5, 1, 1.5, 2, 3, 4, 6, 24 hours postdose (cephalexin)
Reported as:
Mean · L/h
Apparent Total Systemic Clearance After Single or Multiple Extravascular Dosing (CL/F) of Cephalexin Administered With and Without Gilteritinib
L/hGilteritinib 200 mg in Expansion Phase
Cephalexin Alone (Day -1)9.713 ± 3.319
Cephalexin + Gilteritinib (Cycle 1 Day 15)10.58 ± 2.977
Statistical analysis
  • Gilteritinib 200 mg in Expansion Phase · Geometric ls mean ratio: 106.42 · 90% CI 85.28 to 132.81
SecondaryApparent Volume of Distribution During the Terminal Elimination Phase After Single Extravascular Dosing (Vz/F) of Cephalexin Administered With and Without Gilteritinib

Plasma samples were used for pharmacokinetic assessments.

Time frame:
Day -1 and cycle 1 day 15: predose, 0.5, 1, 1.5, 2, 3, 4, 6, 24 hours postdose (cephalexin)
Reported as:
Mean · liters
Apparent Volume of Distribution During the Terminal Elimination Phase After Single Extravascular Dosing (Vz/F) of Cephalexin Administered With and Without Gilteritinib
litersGilteritinib 200 mg in Expansion Phase
Cephalexin Alone (Day -1)24.07 ± 7.173
Cephalexin + Gilteritinib (Cycle 1 Day 15)25.86 ± 5.346
SecondaryAmount of Drug Excreted in Urine (Aelast) of Cephalexin Administered With and Without Gilteritinib

Urine samples were used for pharmacokinetic assessments.

Time frame:
Day -1 and cycle 1 day 15: 0-3 hours, 3-6 hours, 6-24 hours postdose (cephalexin)
Reported as:
Mean · mg
Amount of Drug Excreted in Urine (Aelast) of Cephalexin Administered With and Without Gilteritinib
mgGilteritinib 200 mg in Expansion Phase
Cephalexin Alone (Day -1)548.9 ± 523.7
Cephalexin + Gilteritinib (Cycle 1 Day 15)448.8 ± 306.1
Statistical analysis
  • Gilteritinib 200 mg in Expansion Phase · Geometric ls mean ratio: 83.93 · 90% CI 46.53 to 151.39
SecondaryFraction of Drug Excreted Into Urine in Percentage (%Ae) of Cephalexin Administered With and Without Gilteritinib

Urine samples were used for pharmacokinetic assessments.

Time frame:
Day -1 and cycle 1 day 15: 0-3 hours, 3-6 hours, 6-24 hours postdose (cephalexin)
Reported as:
Mean · percentage
Fraction of Drug Excreted Into Urine in Percentage (%Ae) of Cephalexin Administered With and Without Gilteritinib
percentageGilteritinib 200 mg in Expansion Phase
Cephalexin Alone (Day -1)109.8 ± 104.7
Cephalexin + Gilteritinib (Cycle 1 Day 15)89.75 ± 61.21
SecondaryRenal Clearance (CLr) of Cephalexin in Administered With and Without Gilteritinib

Urine samples were used for pharmacokinetic assessments.

Time frame:
Day -1 and cycle 1 day 15: 0-3 hours, 3-6 hours, 6-24 hours postdose (cephalexin)
Reported as:
Mean · L/h
Renal Clearance (CLr) of Cephalexin in Administered With and Without Gilteritinib
L/hGilteritinib 200 mg in Expansion Phase
Cephalexin Alone (Day -1)8.784 ± 8.727
Cephalexin + Gilteritinib (Cycle 1 Day 15)11.04 ± 8.430
Statistical analysis
  • Gilteritinib 200 mg in Expansion Phase · Geometric ls mean ratio: 82.84 · 90% CI 40.25 to 170.48

Adverse events

Collected over From first dose of study drug up to 30 days after last dose of study drug (median treatment duration was 69.5 days, minimum of 3 days and maximum of 1320 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gilterinib 20 mg in Escalation Phase4/5 (80%)2/5 (40%)5/5 (100%)
Gilterinib 40 mg in Escalation Phase2/3 (66.7%)2/3 (66.7%)2/3 (66.7%)
Gilterinib 80 mg in Escalation Phase3/3 (100%)2/3 (66.7%)3/3 (100%)
Gilterinib 120 mg in Escalation Phase3/3 (100%)1/3 (33.3%)3/3 (100%)
Gilterinib 200 mg in Escalation Phase2/3 (66.7%)2/3 (66.7%)3/3 (100%)
Gilterinib 300 mg in Escalation Phase3/3 (100%)2/3 (66.7%)3/3 (100%)
Gilterinib 450 mg in Escalation Phase3/3 (100%)2/3 (66.7%)3/3 (100%)
Gilterinib 20 mg in Expansion Phase10/12 (83.3%)8/12 (66.7%)12/12 (100%)
Gilterinib 40 mg in Expansion Phase13/13 (100%)12/13 (92.3%)12/13 (92.3%)
Gilterinib 80 mg in Expansion Phase21/21 (100%)19/21 (90.5%)20/21 (95.2%)
Gilterinib 120 mg in Expansion Phase53/66 (80.3%)52/66 (78.8%)62/66 (93.9%)
Gilterinib 200 mg in Expansion Phase82/100 (82%)92/100 (92%)97/100 (97%)
Gilterinib 300 mg in Expansion Phase16/17 (94.1%)14/17 (82.4%)16/17 (94.1%)
Most frequent serious events
Showing 10 of 236
Most frequent serious events
EventGilterinib 20 mg in Escalation PhaseGilterinib 40 mg in Escalation PhaseGilterinib 80 mg in Escalation PhaseGilterinib 120 mg in Escalation PhaseGilterinib 200 mg in Escalation PhaseGilterinib 300 mg in Escalation PhaseGilterinib 450 mg in Escalation PhaseGilterinib 20 mg in Expansion PhaseGilterinib 40 mg in Expansion PhaseGilterinib 80 mg in Expansion PhaseGilterinib 120 mg in Expansion PhaseGilterinib 200 mg in Expansion PhaseGilterinib 300 mg in Expansion Phase
Febrile neutropeniaBlood and lymphatic system disorders0/51/31/31/32/32/30/34/127/135/2118/6635/1004/17
PneumoniaInfections and infestations0/51/30/30/32/30/30/31/121/132/2113/6612/1001/17
Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/52/30/31/30/31/30/32/123/135/219/6620/1004/17
AnaemiaBlood and lymphatic system disorders0/50/30/30/30/30/31/30/120/131/210/664/1000/17
Cardiac arrestCardiac disorders0/50/30/30/30/30/31/30/120/131/210/660/1000/17
DiarrhoeaGastrointestinal disorders0/50/30/30/30/30/31/30/120/131/215/665/1000/17
EnteritisGastrointestinal disorders0/51/30/30/30/30/30/30/120/130/210/660/1000/17
Mucosal inflammationGeneral disorders0/50/30/30/30/31/30/30/120/130/210/661/1001/17
PyrexiaGeneral disorders0/50/30/31/31/31/30/30/120/130/219/669/1001/17
CholecystitisHepatobiliary disorders0/50/30/31/30/30/30/30/120/130/210/660/1000/17
Most frequent other events
Showing 10 of 248
Most frequent other events
EventGilterinib 20 mg in Escalation PhaseGilterinib 40 mg in Escalation PhaseGilterinib 80 mg in Escalation PhaseGilterinib 120 mg in Escalation PhaseGilterinib 200 mg in Escalation PhaseGilterinib 300 mg in Escalation PhaseGilterinib 450 mg in Escalation PhaseGilterinib 20 mg in Expansion PhaseGilterinib 40 mg in Expansion PhaseGilterinib 80 mg in Expansion PhaseGilterinib 120 mg in Expansion PhaseGilterinib 200 mg in Expansion PhaseGilterinib 300 mg in Expansion Phase
FatigueGeneral disorders1/50/31/30/33/31/31/34/125/138/2127/6632/1004/17
ConstipationGastrointestinal disorders1/51/31/32/31/31/30/31/121/135/2112/6632/1001/17
NauseaGastrointestinal disorders2/50/32/30/30/30/30/31/123/134/2115/6628/1001/17
VomitingGastrointestinal disorders1/50/32/30/30/30/30/32/121/135/2113/6622/1001/17
Aspartate aminotransferase increasedInvestigations0/50/31/30/31/31/32/31/121/133/2120/6635/1001/17
Decreased appetiteMetabolism and nutrition disorders0/50/32/30/30/30/30/31/121/133/2111/6619/1001/17
HyperglycaemiaMetabolism and nutrition disorders1/50/30/31/30/30/32/30/120/130/215/6614/1000/17
PollakiuriaRenal and urinary disorders0/50/30/30/30/32/30/30/121/130/210/667/1000/17
DiarrhoeaGastrointestinal disorders0/50/31/31/30/31/31/31/122/135/2127/6645/1005/17
HypokalaemiaMetabolism and nutrition disorders1/50/31/30/30/31/30/35/122/132/2110/6625/1000/17

Baseline characteristics

The analysis population was the safety analysis set (SAF), which consisted of all participants who received at least 1 dose of study drug and excluded re-enrolled participants.

Age, Continuous
Age, Continuous(years)Gilteritinib 20 mg in Escalation PhaseGilteritinib 40 mg in Escalation PhaseGilteritinib 80 mg in Escalation PhaseGilteritinib 120 mg in Escalation PhaseGilteritinib 200 mg in Escalation PhaseGilteritinib 300 mg in Escalation PhaseGilteritinib 450 mg in Escalation PhaseGilteritinib 20 mg in Expansion PhaseGilteritinib 40 mg in Expansion PhaseGilteritinib 80 mg in Expansion PhaseGilteritinib 120 mg in Expansion PhaseGilteritinib 200 mg in Expansion PhaseGilteritinib 300 mg in Expansion PhaseTotal
Mean65.8 ± 6.856.7 ± 6.761 ± 8.761.7 ± 664 ± 155.3 ± 2561.7 ± 10.759.3 ± 15.659.6 ± 1456.3 ± 18.158.3 ± 16.759.8 ± 14.657.7 ± 15.959 ± 15.1
Sex: Female, Male
Sex: Female, Male(Participants)Gilteritinib 20 mg in Escalation PhaseGilteritinib 40 mg in Escalation PhaseGilteritinib 80 mg in Escalation PhaseGilteritinib 120 mg in Escalation PhaseGilteritinib 200 mg in Escalation PhaseGilteritinib 300 mg in Escalation PhaseGilteritinib 450 mg in Escalation PhaseGilteritinib 20 mg in Expansion PhaseGilteritinib 40 mg in Expansion PhaseGilteritinib 80 mg in Expansion PhaseGilteritinib 120 mg in Expansion PhaseGilteritinib 200 mg in Expansion PhaseGilteritinib 300 mg in Expansion PhaseTotal
Female2111210841237495123
Male3222123499295112129
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Gilteritinib 20 mg in Escalation PhaseGilteritinib 40 mg in Escalation PhaseGilteritinib 80 mg in Escalation PhaseGilteritinib 120 mg in Escalation PhaseGilteritinib 200 mg in Escalation PhaseGilteritinib 300 mg in Escalation PhaseGilteritinib 450 mg in Escalation PhaseGilteritinib 20 mg in Expansion PhaseGilteritinib 40 mg in Expansion PhaseGilteritinib 80 mg in Expansion PhaseGilteritinib 120 mg in Expansion PhaseGilteritinib 200 mg in Expansion PhaseGilteritinib 300 mg in Expansion PhaseTotal
Black or African American000110010424316
White523213310914579113213
Asian01001000001407
Other000000014361116
Ethnicity
Ethnicity(Participants)Gilteritinib 20 mg in Escalation PhaseGilteritinib 40 mg in Escalation PhaseGilteritinib 80 mg in Escalation PhaseGilteritinib 120 mg in Escalation PhaseGilteritinib 200 mg in Escalation PhaseGilteritinib 300 mg in Escalation PhaseGilteritinib 450 mg in Escalation PhaseGilteritinib 20 mg in Expansion PhaseGilteritinib 40 mg in Expansion PhaseGilteritinib 80 mg in Expansion PhaseGilteritinib 120 mg in Expansion PhaseGilteritinib 200 mg in Expansion PhaseGilteritinib 300 mg in Expansion PhaseTotal
Not Hispanic or Latino5323333111220629717241
Hispanic or Latino001000011143011
Duration of Disease (AML)
Duration of Disease (AML)(months)Gilteritinib 20 mg in Escalation PhaseGilteritinib 40 mg in Escalation PhaseGilteritinib 80 mg in Escalation PhaseGilteritinib 120 mg in Escalation PhaseGilteritinib 200 mg in Escalation PhaseGilteritinib 300 mg in Escalation PhaseGilteritinib 450 mg in Escalation PhaseGilteritinib 20 mg in Expansion PhaseGilteritinib 40 mg in Expansion PhaseGilteritinib 80 mg in Expansion PhaseGilteritinib 120 mg in Expansion PhaseGilteritinib 200 mg in Expansion PhaseGilteritinib 300 mg in Expansion PhaseTotal
Mean19.70 ± 24.6210.81 ± 8.5862.46 ± 6.9749.53 ± 72.179.46 ± 2.2319.75 ± NA7.21 ± 4.2711.3 ± 6.6110.53 ± 11.2216.3 ± 9.8512.65 ± 11.3310.9 ± 9.9412.09 ± 17.7613.16 ± 14.97
Local FLT3 Mutation Status
Local FLT3 Mutation Status(Participants)Gilteritinib 20 mg in Escalation PhaseGilteritinib 40 mg in Escalation PhaseGilteritinib 80 mg in Escalation PhaseGilteritinib 120 mg in Escalation PhaseGilteritinib 200 mg in Escalation PhaseGilteritinib 300 mg in Escalation PhaseGilteritinib 450 mg in Escalation PhaseGilteritinib 20 mg in Expansion PhaseGilteritinib 40 mg in Expansion PhaseGilteritinib 80 mg in Expansion PhaseGilteritinib 120 mg in Expansion PhaseGilteritinib 200 mg in Expansion PhaseGilteritinib 300 mg in Expansion PhaseTotal
Negative100111118121310958
Positive4332222115953908194
08

Study locations

26 sites
  • Site US10021
    Birmingham, Alabama 35294, United States
  • Site US10023
    Scottsdale, Arizona 85259, United States
  • Site US10022
    Duarte, California 91010, United States
  • Site US10008
    Los Angeles, California 90095-1678, United States
  • Site US10005
    San Francisco, California 94143, United States
  • Site US10001
    Chicago, Illinois 60611, United States
  • Site US10015
    Chicago, Illinois 60637, United States
  • Site US10012
    Baltimore, Maryland 21201, United States
  • Site US10003
    Baltimore, Maryland 21287, United States
  • Site US10006
    Minneapolis, Minnesota 55455, United States
  • Site US10011
    Rochester, Minnesota 55905, United States
  • Site US10020
    Hackensack, New Jersey 07601, United States
  • Site US10010
    Buffalo, New York 14263, United States
  • Site US10009
    New York, New York 10022, United States
  • Site US10013
    New York, New York 10032, United States
  • Site US10019
    New York, New York 10065, United States
  • Site US10014
    Cleveland, Ohio 44195, United States
  • Site US10018
    Hershey, Pennsylvania 17033, United States
  • Site US10004
    Philadelphia, Pennsylvania 19104, United States
  • Site US10017
    Charleston, South Carolina 29425-8900, United States
  • Site US10007
    Nashville, Tennessee 37232, United States
  • Site US10002
    Houston, Texas 77030, United States
  • Site US10026
    Fairfax, Virginia 22031, United States
  • Site DE49002
    Berlin, 12203, Germany
  • Site DE49004
    Dresden, 01307, Germany
  • Site IT39001
    Bologna, 40138, Italy
09

References and documents

Publications

  • James AJ, Smith CC, Litzow M, Perl AE, Altman JK, Shepard D, Kadokura T, Souda K, Patton M, Lu Z, Liu C, Moy S, Levis MJ, Bahceci E. Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clin Pharmacokinet. 2020 Oct;59(10):1273-1290. doi: 10.1007/s40262-020-00888-w. Erratum In: Clin Pharmacokinet. 2021 Sep;60(9):1251. doi: 10.1007/s40262-021-01060-8. PubMed 32304015 ↗
  • Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Rollig C, Neubauer A, Martinelli G, Bahceci E, Levis M. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20. PubMed 28645776 ↗
  • Kasi PM, Litzow MR, Patnaik MM, Hashmi SK, Gangat N. Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets. Leuk Res Rep. 2016 Jan 12;5:7-10. doi: 10.1016/j.lrr.2016.01.002. eCollection 2016. PubMed 26904404 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Aug 2017, 45 months.

Results were first posted in Feb 2019, 1 year 6 months after primary completion. A results delay was requested in Nov 2016.

Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's 45 months is below that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2013
First posted
Dec 18, 2013
StartActual
Oct 9, 2013
Primary completionActual
Aug 4, 2017
CompletionActual
Mar 7, 2018
Results delay requested
Nov 16, 2016
Results first posted
Feb 20, 2019
Last update
Dec 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02014558
Responsible party
Sponsor
First posted
Dec 18, 2013
Start date
Oct 9, 2013
Primary completion
Aug 4, 2017
Completion
Mar 7, 2018
Results posted
Feb 20, 2019
Last update
Dec 3, 2024

Study contacts

Executive Medical Director
study director · Astellas Pharma Global Development

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gilteritinib

Start the discussion